ArticleDiscover oncology2025
Deciphering the causal relationships between plasma metabolites, peripheral cells, inflammatory factors and DLBCL for discovering novel therapeutic targets.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling novel therapeutic targets for diffuse large B-cell lymphoma: a plasma multi-omics study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) is defined as a highly heterogeneous type of lymphoma which lacks specific biomarkers and drug targets. Past studies revealed changes in plasma metabolites, immune cells and inflammatory factors in the development of DLBCL, yet findings remain inconsistent. Our study aims to elucidate the mediating effects of peripheral cells and inflammatory factors on the relationship between metabolites and DLBCL, and offer therapeutic targets for DLBCL treatment.
methodsWe evaluated the association between plasma metabolites, peripheral cells, inflammatory factors and DLBCL risk using two-sample Mendelian randomization (MR) analysis. The proportion of peripheral cells and inflammatory factors in the metabolite-DLBCL axis was further calculated. Sensitivity analyses were conducted to validate the robustness of the results. Besides, summary data-based Mendelian randomization (SMR) analysis and heterogeneity in dependent instruments (HEIDI) test were performed to identify potential drug targets. Further more, in silico docking and molecular dynamic (MD) simulation studies were presented to elucidate the mode of interaction of the top predicted drugs.
resultsMR analysis identified a total of 52 plasma metabolites, 58 peripheral cells and 8 inflammatory factors that were genetically associated with DLBCL. We subsequently identified 6 mediated relationships, with 5 immune cells acting as potential mediators between 6 metabolites and DLBCL. Sensitivity analyses confirmed the robustness of these associations. Further SMR analysis and HEIDI test revealed 5 target genes existed correlation with DLBCL-related metabolites. Additionally, stable drug-target complexes were identified by utilizing molecular docking and dynamic simulation.
conclusionThis study revealed a significant causal link between plasma metabolites, peripheral cells, inflammatory factors and DLBCL. It remarkably enhances our understanding of the interplay between immune responses, metabolites and DLBCL risk, providing insights into the development of therapeutic strategies from the metabolite-immune axis alternation perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.